PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 12, 2022JAMA Neurology206 citationsOpen Access

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes

SSSergey ShcherbininCECynthia EvansMLMing‐Chi Lu

Key Points

Key points are not available for this paper at this time.

Abstract

ClinicalTrials.gov Identifier: NCT03367403.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Shcherbinin et al. (2022) studied this question.

synapsesocial.com/papers/69ded00f800448099bb0be6ahttps://doi.org/10.1001/jamaneurol.2022.2793
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Donanemab in Early Alzheimer’s Disease2021 · 1,763 citations
  2. 2Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.1997 · 494 citations
  3. 3Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale2018 · 238 citations
  4. 4Untitled2021 · 21 citations
  5. 5Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition2017 · 363 citations